RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations

L. Conejero Hall (Madrid, Spain), L. Puente Maestu (Madrid, Spain), M. Calle Rubio (Madrid, Spain), W. Girón (Madrid, Spain), C. Alvarez Martínez (Madrid, Spain), M. Buendía García (Madrid, Spain), J. Serra Batllés (Barcelona, Spain), J. Rodríguez Hermosa (Madrid, Spain), S. Alonso Viteri (Madrid, Spain), J. García De Pedro (Madrid, Spain), P. Benedetti (Madrid, Spain), J. De Miguel Díez (Madrid, Spain), J. Alvarez-Sala Walther (Madrid, Spain), J. Hernández Vázquez (Madrid, Spain), F. García Río (Madrid, Spain), C. Rodríguez Sainz (Madrid, Spain), C. Fernández Pérez (La Coruña, Spain), A. Doyle (Madrid, Spain), R. Caballero (Madrid, Spain), J. Subiza (Madrid, Spain), M. Casanovas (Madrid, Spain), E. Fernández-Cruz (Madrid, Spain)

Source: Virtual Congress 2021 – ALERT: COPD
Session: ALERT: COPD
Session type: Clinical trials session
Number: 207

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Conejero Hall (Madrid, Spain), L. Puente Maestu (Madrid, Spain), M. Calle Rubio (Madrid, Spain), W. Girón (Madrid, Spain), C. Alvarez Martínez (Madrid, Spain), M. Buendía García (Madrid, Spain), J. Serra Batllés (Barcelona, Spain), J. Rodríguez Hermosa (Madrid, Spain), S. Alonso Viteri (Madrid, Spain), J. García De Pedro (Madrid, Spain), P. Benedetti (Madrid, Spain), J. De Miguel Díez (Madrid, Spain), J. Alvarez-Sala Walther (Madrid, Spain), J. Hernández Vázquez (Madrid, Spain), F. García Río (Madrid, Spain), C. Rodríguez Sainz (Madrid, Spain), C. Fernández Pérez (La Coruña, Spain), A. Doyle (Madrid, Spain), R. Caballero (Madrid, Spain), J. Subiza (Madrid, Spain), M. Casanovas (Madrid, Spain), E. Fernández-Cruz (Madrid, Spain). RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations. 207

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009


A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial
Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care
Year: 2017



Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial
Source: Eur Respir J 2002; 20: Suppl. 38, 146s
Year: 2002

Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


Recombinant human deoxyribonuclease (rhDNase) for the treatment of acute asthma in children: a multicentre randomised double-blind clinical trial
Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up
Year: 2007


Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial
Source: International Congress 2016 – Asthma management
Year: 2016


Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006